USPTO Examiner WARD PAUL V - Art Unit 1622

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18927346COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVESOctober 2024April 2025Allow611YesNo
18710989MELAMINE PROCESS WITH A TWO-STAGE PURIFICATION OF MELAMINE OFFGASMay 2024June 2025Allow1300NoNo
18626881REAGENTS FOR QUANTITATIVE MASS SPECTROMETRYApril 2024September 2024Allow511NoNo
18618311Pharmaceutical Compositions Having Improved Storage StabilityMarch 2024February 2025Allow1010NoNo
18606994INJECTABLE GOLD-BASED PHARMACEUTICAL COMPOSITIONMarch 2024July 2024Allow501NoNo
18606165PHARMACEUTICAL COMPOSITION WITH PRIMARY AND SECONDARY THERAPEUTIC AGENTSMarch 2024July 2024Allow501NoNo
18604731N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDSMarch 2024June 2025Abandon1501YesNo
18443509METALLOENZYME INHIBITOR COMPOUNDSFebruary 2024March 2025Allow1311NoNo
18433881THERAMUTEIN MODULATORSFebruary 2024October 2024Allow800NoNo
18422704DOSING OF KRAS INHIBITOR FOR TREATMENT OF CANCERSJanuary 2024June 2025Abandon1710NoNo
18395738METHOD OF PREPARING CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVESDecember 2023January 2025Allow1210NoNo
18395739METHOD OF INHIBITING KINASE BY CAMSYLATE SALTS OF TRIAZOLOPYRAZINE DERIVATIVESDecember 2023January 2025Allow1210YesNo
18519150SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITYNovember 2023April 2025Allow1611NoNo
18513888CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENTNovember 2023February 2025Allow1501NoNo
185105947-IMINO-5-(1H-INDOL-3-YL)-1,3-SUBSTITUTED-7,8-DIHDROPYRIMIDO[4,5-D]PYRIMIDINE-2,4(1H,3H)-DIONE AS ANTI-INFLAMMATORY AGENTSNovember 2023July 2024Allow811NoNo
18504778ORAL COMPOSITIONS OF MK2 PATHWAY INHIBITOR FOR TREATMENT OF IMMUNE CONDITIONSNovember 2023March 2025Allow1621YesNo
18500735METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTICNovember 2023September 2024Allow1111NoNo
18496043NEW COMPOUNDS AND METHODS OF THEIR MANUFACTURINGOctober 2023August 2024Allow1010YesNo
18383992COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMSOctober 2023June 2025Allow2011NoNo
18383301PYRROLOPYRIMIDINE ITK INHIBITORSOctober 2023January 2025Allow1411NoNo
18469860Compounds and Methods of Their ManufacturingSeptember 2023August 2024Allow1111YesNo
18309867MODULATORS OF ALPHA-SYNUCLEIN PROTEOLYSIS AND ASSOCIATED METHODS OF USESeptember 2023January 2025Allow2011NoNo
18467185CHEMICAL COMPOUNDSSeptember 2023May 2025Allow2011YesNo
18226570POLYMORPHS OF SELINEXORJuly 2023March 2025Allow2010NoNo
18219511CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITHJuly 2023October 2024Allow1501NoNo
18214825DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USEJune 2023February 2025Allow1911NoNo
18207887METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVESJune 2023January 2025Allow1911NoNo
18319402CRYSTALLINE FORMS OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE APROCITENTANMay 2023January 2025Allow2011NoNo
18197361COMPOUNDS AND METHODS OF IDENTIFYING, SYNTHESIZING, OPTIMIZING AND PROFILING PROTEIN MODULATORSMay 2023June 2025Abandon2511YesNo
18306515SYNTHETIC ROUTE TO SCOPOLAMINE AND/OR ATROPINEApril 2023January 2025Allow2011NoNo
18301693QUINOXALINE COMPOUNDS AND USES THEREOFApril 2023January 2025Allow2111NoNo
18300501CRYSTALLINE FORMS OF GSK1278863, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOFApril 2023January 2025Abandon2101NoNo
18300141CRYSTALSApril 2023January 2025Abandon2101NoNo
18299622PROCESS FOR PREPARING BTK INHIBITORSApril 2023December 2024Abandon2010NoNo
18125826QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORSMarch 2023January 2025Allow2111NoNo
18121886THIENOPYRIMIDINE DERIVATIVES AND PRODUCTION METHODS THEREOFMarch 2023August 2024Allow1711YesNo
18118549Chemical Process for the Synthesis of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolineMarch 2023January 2025Abandon2201NoNo
18175272CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALTFebruary 2023February 2025Abandon2401NoNo
18163151SALT FORMS AND POLYMORPHS OF (R)-1-(4-(6-(2-(4-(3,3-DIFLUOROCYCLOBUTOXY)-6-METHYLPYRIDIN-2-YL)ACETAMIDO) PYRIDAZIN-3-YL)-2-FLUOROBUTYL)-N-METHYL-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDEFebruary 2023November 2024Allow2110NoNo
18159494DOSAGE REGIME AND METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSIONJanuary 2023January 2025Abandon2401NoNo
18099611NOVEL BARBITURIC ACID DERIVATIVES, THEIR PREPARATION AND USE THEREOF AS LEUKOCYTE TRANSMIGRATION INHIBITORS AND FOR TREATING INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES AND CANCERJanuary 2023November 2024Allow2221NoNo
18017201SYNTHESIS OF HETEROCYCLIC COMPOUNDS FROM CARBOXAMIDE AND CARBOXAMIDE DERIVATIVES WITH HALOALKANOLSJanuary 2023June 2025Allow2901NoNo
18146294COMPOUNDS, CONJUGATES, AND COMPOSITIONS OF EPIPOLYTHIODIKETOPIPERAZINES AND POLYTHIODIKETOPIPERAZINES AND USES THEREOFDecember 2022August 2024Allow1911NoNo
18068788PEPTIDE PHARMACEUTICALS FOR TREATMENT OF NASH AND OTHER DISORDERSDecember 2022October 2024Allow2220NoNo
180815581H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFORDecember 2022December 2024Abandon2420YesNo
18077315TOPICAL TREATMENT OF VITILIGO BY A JAK INHIBITORDecember 2022January 2025Allow2510NoNo
17986350TREATMENT OF THE GASTROINTESTINAL TRACT WITH DIMERIC NAPHTHALIMIDE COMPOUNDSNovember 2022January 2025Allow2611NoNo
18055017TREATMENT FOR OBESITYNovember 2022September 2024Allow2211NoNo
17983097SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORSNovember 2022November 2024Abandon2411NoNo
17980291HISTONE DEMETHYLASE INHIBITORSNovember 2022August 2024Allow2211NoNo
18051216HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERSOctober 2022August 2024Allow2111NoNo
17963036DIHYDROPYRIDINES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT OR TRAUMATIC BRAIN INJURYOctober 2022October 2024Allow2411NoNo
179597503-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAMEOctober 2022January 2025Abandon2711NoNo
17957549Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancerSeptember 2022November 2024Allow2521NoNo
17957932TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOLSeptember 2022August 2024Allow2310NoNo
17936555SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITORSeptember 2022November 2024Allow2510NoNo
17913915PROCESS FOR THE SYNTHESIS OF LOFEXIDINESeptember 2022March 2025Allow2900NoNo
17931608USE OF DIANTHRONE COMPOUND IN PREPARATION OF MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF MYOCARDIAL ISCHEMIC DISEASE AND RELATED DISEASE THEREOFSeptember 2022December 2024Abandon2711YesNo
17942829SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORSSeptember 2022October 2024Allow2511NoNo
17940902N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseasesSeptember 2022August 2024Allow2311NoNo
17899877Compounds Useful in HIV TherapyAugust 2022July 2024Allow2311NoNo
17820779SALTS OF 2-FLUORO-N-METHYL-4-[7-(QUINOLIN-6-YL-METHYL)- IMIDAZO[1,2-B][1,2,4]TRIAZIN-2-YL]BENZAMIDE AND PROCESSES RELATED TO PREPARING THE SAMEAugust 2022May 2025Allow3311NoNo
17798406Polymorphic Form of (-)-Cibenzoline SuccinateAugust 2022June 2025Allow3501NoNo
17876138Stilbene Derivative and Method for Preparing SameJuly 2022August 2024Allow2411YesNo
17858701CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDEJuly 2022November 2024Allow2811YesNo
17858713CRYSTALLINE FORMS OF N-[4-(CHLORODIFLUOROMETHOXY)PHENYL]-6-[(3R)-3-HYDROXYPYRROLIDIN-1-YL]-5-(1H-PYRAZOL-5-YL)PYRIDINE-3-CARBOXAMIDEJuly 2022September 2024Allow2711NoNo
17851528SMARCA DEGRADERS AND USES THEREOFJune 2022October 2024Allow2711NoNo
17847490GLUTAMATE TRANSPORTER ACTIVATORS AND METHODS USING SAMEJune 2022July 2024Allow2511NoNo
17778510NOVEL PHTHALOCYANINE NANOWIRES AND USES THEREFORMay 2022June 2025Allow3701YesNo
17738739Tripartite Modulators of Endosomal G Protein-Coupled ReceptorsMay 2022November 2024Abandon3011NoNo
17763974XANTHINE CB1 INHIBITORSMarch 2022March 2025Abandon3501YesNo
17698505ACTIVATING PYRUVATE KINASE RMarch 2022April 2024Allow2520YesNo
17639100TRIAZINANE DERIVATIVES AND METHODS OF MAKING THEMFebruary 2022May 2025Allow3801NoNo
17633989NEW CRYSTAL FORM OF AN ORGANIC FLUORESCENT COMPOUNDFebruary 2022May 2025Allow3910NoNo
17633544STABLE POLYMORPHIC FORM OF 6-FLUORO-9-METHYL-9H-B-CARBOLINE AND USES THEREOFFebruary 2022June 2025Allow4010YesNo
17579443CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOFJanuary 2022September 2024Allow3211NoNo
17625273PROCESS OF PREPARING 2-(PHENYLIMINO)-1,3-THIAZOLIDIN-4-ONESJanuary 2022March 2025Abandon3801NoNo
17624949MACROCYCLIC SPIROCYCLE DERIVATIVES AS MCL-1 INHIBITORSJanuary 2022February 2025Allow3711NoNo
17624572THIENOPYRIMIDINE DERIVATIVES HAVING STEREO CONFIGURATIONS AND USE THEREOF IN MEDICINEJanuary 2022June 2025Allow4111YesNo
17620885SALT FORMS OF BEMPEDOIC ACID AND METHODS FOR USING THE SAMEDecember 2021February 2025Allow3810NoNo
17615127Hydroxy-Functionalized Triazine Compounds, Curable Fluoropolymer Compositions Comprising Such Compounds and Cured Articles TherefromNovember 2021June 2025Allow4301NoNo
17615013Treatment Method Using A Complex of Angiotensin II Receptor Antagonist Metabolite and NEP InhibitorNovember 2021June 2025Allow4311NoNo
17595817Drp1-FILAMIN COMPLEX FORMATION INHIBITORSNovember 2021June 2025Allow4311NoNo
17612899ADMINISTRATION METHOD AND DOSAGE REGIMEN FOR TREATMENT OF NEURODEGENERATIVE DISEASES USING TRAMETINIB AND MARKERSNovember 2021June 2025Abandon4301NoNo
17595612DI-FLUORO AZEPANES AS HBV CAPSID ASSEMBLY MODULATORSNovember 2021March 2025Abandon4001NoNo
17527448CRYSTALLINE SPIROCYCLIC COMPOUND, A DOSAGE FORM CONTAINING, A METHOD FOR USING IN TREATMENT OF DISEASE, AND A METHOD FOR RECRYSTALLIZINGNovember 2021February 2025Abandon3901NoNo
17527907METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZANovember 2021February 2025Abandon3901NoNo
17611458SALTS OF A CLASS OF PYRIMIDINE COMPOUNDS, POLYMORPHS, AND PHARMACEUTICAL COMPOSITIONS THEREOF, PREPARATION METHODS THEREFOR AND USES THEREOFNovember 2021March 2025Abandon4001NoNo
17610041NOVEL TREATMENT FOR WOLFRAM SYNDROMENovember 2021March 2025Allow4011NoNo
176100222,3-DIARYL-1,3-THIAZEPAN-4-ONES COMPOUNDS AND METHODS FOR MAKINGNovember 2021December 2024Allow3701NoNo
17607917PLANT PARASITIC NEMATODE CONTROL AGENT AND METHOD FOR CONTROLLING PLANT PARASITIC NEMATODENovember 2021June 2025Allow4311NoNo
17605801ALLOSTERIC ACTIVATORS OF THE ALPHA1A-ADRENERGIC RECEPTOROctober 2021April 2025Allow4202NoNo
17602344NANOPARTICLES COMPRISING COPOLYMERIC OR HOMOPOLYMERIC COMPOUNDS WHICH COMPRISE CYANOACRYLATE SUBUNITSOctober 2021May 2025Allow4311NoNo
17602025ENHANCED PERFORMANCE OF AMORPHOUS SOLID AND SOLUBILIZED FORMULATIONS FOR ACHIEVING THERAPEUTIC PLASMA CONCENTRATIONSOctober 2021June 2025Allow4411YesNo
17600860MULTICOMPONENT CRYSTAL FORMULATIONSOctober 2021February 2025Abandon4101YesNo
17470703PHTHALAZINONE DERIVATIVESSeptember 2021October 2024Abandon3711NoNo
17433073SOLID STATE FORMS OF SIPONIMODAugust 2021February 2025Abandon4201NoNo
17401570SALTS OF TAM INHIBITORSAugust 2021August 2024Allow3620NoNo
17376577Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of CancerJuly 2021July 2024Allow3621NoNo
17335960COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASESJune 2021December 2024Abandon4221NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WARD, PAUL V.

Strategic Value of Filing an Appeal

Total Appeal Filings
16
Allowed After Appeal Filing
8
(50.0%)
Not Allowed After Appeal Filing
8
(50.0%)
Filing Benefit Percentile
75.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner WARD, PAUL V - Prosecution Strategy Guide

Executive Summary

Examiner WARD, PAUL V works in Art Unit 1622 and has examined 547 patent applications in our dataset. With an allowance rate of 94.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner WARD, PAUL V's allowance rate of 94.9% places them in the 85% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WARD, PAUL V receive 1.29 office actions before reaching final disposition. This places the examiner in the 24% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WARD, PAUL V is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a -1.3% benefit to allowance rate for applications examined by WARD, PAUL V. This interview benefit is in the 7% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 46.8% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 81.6% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 78.0% are granted (fully or in part). This grant rate is in the 91% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 10.1% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 28.9% of allowed cases (in the 95% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.